Valuation: Simulations Plus, Inc.

Market Cap 369M 322M 298M 273M 518M 35.53B 527M 3.55B 1.4B 17.35B 1.38B 1.35B 59.9B P/E 2026 *
43.4x
P/E 2027 * 39.8x
Enterprise Value 369M 322M 298M 273M 518M 35.53B 527M 3.55B 1.4B 17.35B 1.38B 1.35B 59.9B EV / Sales 2026 *
4.5x
EV / Sales 2027 * 4.27x
Free-Float
82.81%
Yield 2026 *
-
Yield 2027 * -
1 day-0.11%
1 week-0.22%
Current month-0.44%
1 month+11.36%
3 months+24.52%
6 months-10.02%
1 week 18.22
Extreme 18.215
18.4
1 month 18.1
Extreme 18.1
18.68
Current year 11.09
Extreme 11.09
21.01
1 year 11.09
Extreme 11.09
21.01
3 years 11.09
Extreme 11.09
52.69
5 years 11.09
Extreme 11.09
67.59
10 years 7.68
Extreme 7.68
90.92
Manager TitleAgeSince
Chief Executive Officer 67 26/06/2018
Director of Finance/CFO 63 01/12/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 81 17/07/1996
Director/Board Member 58 03/12/2014
Chairman 76 17/12/2024
Date Insider Type Main position Quantity % Market Cap.
6/7/26 Sell

Executive/Senior Manager

-1,000 0.0050%
1/7/26 Sell

Founder

-4,177 0.0207%
16/6/26 Fiscal year

Executive/Senior Manager

22,050 0.1094%
Change 5-day change 1-year change 3-year change Capi.($)
-0.11%-0.22%+40.56%-61.69% 369M
+1.91%+4.89%-29.34%-5.42% 31.46B
+0.18%-7.60%-41.11%+194.93% 14.08B
-1.06%-0.85%-23.13%+66.79% 5.65B
-4.70%-0.69% - - 2.35B
+0.38%+4.17%+72.54%-35.06% 2.13B
-2.91%-13.93% - - 1.8B
+3.15%+1.69%-32.76% - 1.08B
+3.95%-9.20%+51.44%+112.56% 901M
-19.62%-21.25%-50.37%+171.82% 795M
Average -1.87%-2.56%-1.52%+63.42% 6.06B
Weighted average by Cap. +0.57%-0.88%-26.43%+55.83%

Financials

2026 *2027 *
Net sales 81.87M 71.56M 66.18M 60.73M 115M 7.89B 117M 789M 310M 3.85B 307M 301M 13.3B 86.26M 75.4M 69.73M 63.98M 121M 8.31B 123M 832M 327M 4.06B 324M 317M 14.01B
Net income 9.53M 8.33M 7.71M 7.07M 13.38M 919M 13.62M 91.91M 36.1M 449M 35.8M 35.02M 1.55B 10.18M 8.9M 8.23M 7.55M 14.29M 981M 14.54M 98.15M 38.56M 479M 38.23M 37.39M 1.65B
Net Debt - -
Logo Simulations Plus, Inc.
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
213
Date Price Change Volume
16/07/26 USD 18.23 -0.11% 371,789
15/07/26 USD 18.25 +0.16% 207,915
14/07/26 USD 18.22 -0.16% 617,725
13/07/26 USD 18.25 +0.05% 394,365
10/07/26 USD 18.24 -0.55% 423,570
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
18.23USD
Average target price
17.25USD
Spread / Average Target
-5.38%

Quarterly revenue - Rate of surprise